Posts for Aptevo Therapeutics Inc. ($APVO)

Explore Aptevo Therapeutics Inc.'s Q4 2024 financial report highlighting a net loss of $24.13M, declining cash reserves, and strategic partnerships amid operational challenges.

Discover essential insights from Aptevo Therapeutics Inc.'s 8-K filing dated February 14, 2025. Get the latest updates for informed investment decisions.

Explore Aptevo Therapeutics Inc.'s 8-K report filed on February 11, 2025, highlighting significant corporate events affecting stock performance. Stay informed with crucial updates.